BioPorto A/S (CPH:BIOPOR)
Denmark
· Delayed Price · Currency is DKK 1.500
+0.006 (0.40%)
Feb 21, 2025, 4:59 PM CET
BioPorto Revenue
BioPorto had revenue of 9.69M DKK in the quarter ending September 30, 2024, with 12.50% growth. This brings the company's revenue in the last twelve months to 34.91M, up 5.49% year-over-year. In the year 2023, BioPorto had annual revenue of 30.96M with 6.87% growth.
Revenue (ttm)
34.91M
Revenue Growth
+5.49%
P/S Ratio
16.90
Revenue / Employee
969.61K
Employees
29
Market Cap
644.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 30.96M | 1.99M | 6.87% |
| Dec 31, 2022 | 28.97M | 4.72M | 19.44% |
| Dec 31, 2021 | 24.25M | 1.05M | 4.53% |
| Dec 31, 2020 | 23.20M | -3.42M | -12.84% |
| Dec 31, 2019 | 26.62M | 606.00K | 2.33% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 290.40B |
| Coloplast | 27.45B |
| Genmab | 21.53B |
| Demant | 22.42B |
| Zealand Pharma | 76.87M |
| H. Lundbeck | 22.00B |
| Ambu A/S | 5.65B |
| ALK-Abelló | 5.54B |
BioPorto News
- 24 days ago - BioPorto A/S appoints new interim Chairman of the Board - GlobeNewsWire
- 4 weeks ago - BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals - GlobeNewsWire
- 2 months ago - BioPorto commences process to appoint new Chair of the Board of Directors - GlobeNewsWire
- 3 months ago - BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024 - GlobeNewsWire
- 3 months ago - BioPorto A/S to Host Third Quarter 2024 Earnings Webcast - GlobeNewsWire
- 3 months ago - BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences - GlobeNewsWire
- 4 months ago - First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital - GlobeNewsWire
- 4 months ago - BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests - GlobeNewsWire